Hyperbaric oxygen therapy (HBOT) for traumatic brain injury has a split evidence base. For acute severe TBI, pooled trial data show a 31 percent mortality reduction. For chronic mild TBI and post-concussion syndrome, results depend on pressure: the largest double-blind trial to date, Weaver 2025, found HBOT improved neurobehavioral symptom scores 10.6 points versus 3.6 for sham (p=0.01), yet several military trials at higher pressure found no benefit over sham.
TBI-related deaths in the US in 2021 (CDC)
Mortality reduction in severe TBI with HBOT, NNT=7 (Cochrane 2012)
NSI symptom improvement, HBOT vs sham (Weaver 2025)
Out-of-pocket cost for a 40 to 60 session course
TBI is one of the most actively studied indications in hyperbaric medicine, with parallel research programs in military and civilian settings. A 2026 comprehensive review by Jusoh and colleagues in Undersea and Hyperbaric Medicine synthesized 74 studies published from 2015 to 2024 and described the evidence as mixed but promising, calling for protocol standardization before HBOT enters routine TBI care.12 The sections below separate the strong findings from the contested ones by injury type, timing, and pressure.
How big is the TBI problem?
Traumatic brain injury caused 69,473 deaths in the United States in 2021, roughly 190 per day, and led to about 214,000 hospitalizations in 2020, per CDC surveillance.11 Adults 75 and older carry the highest burden. In the military, more than 459,000 service members have been diagnosed with TBI since 2000, most classified as mild.
Most TBIs are mild, yet a meaningful minority do not fully recover. Boussi-Gross and colleagues noted that 70 to 90 percent of TBIs are mild, and up to 25 percent of those patients develop chronic neurocognitive impairment months to years later.13 That persistent group, along with survivors of severe injury, is where HBOT has been tested most. The scale of unmet need explains the sustained research interest despite HBOT remaining an off-label, out-of-pocket option for brain injury.
Does HBOT reduce TBI mortality?
For severe TBI, yes. The 2012 Cochrane review by Bennett and colleagues pooled seven randomized trials and 571 patients and found HBOT reduced the risk of death by 31 percent (relative risk 0.69, 95% CI 0.54 to 0.88), a number needed to treat of seven. This is the strongest single mortality signal in the field.3
The same review reported a Glasgow Coma Scale improvement of 2.68 points (95% CI 1.84 to 3.52) and a lower rate of unfavorable outcome at one month. The authors were careful, however: they concluded that routine use could not yet be justified, because survivors did not consistently show better functional outcomes and because HBOT carried a pulmonary risk signal (13 percent of treated patients versus 0 percent of controls in one trial). Mortality benefit and functional benefit are not the same claim, and the review supported the first more than the second.
Newer severe-TBI work reinforces the biological rationale. Rockswold and colleagues ran a prospective randomized Phase II trial (Journal of Neurosurgery, 2013) showing combined hyperbaric and normobaric hyperoxia improved cerebral metabolism, lowered intracranial pressure, and produced better clinical outcomes than standard neurosurgical care.15 An earlier Rockswold randomized trial (1992) had already linked HBOT to reduced mortality in severely injured patients.16 A 2018 systematic review by Daly and colleagues in Journal of Neurotrauma concluded HBOT has genuine potential as an acute-phase treatment for severe TBI while flagging the need for a definitive trial.17
What does the research say by TBI type?
Evidence quality varies sharply across TBI categories. Acute severe and moderate injury show the clearest benefit, chronic mild TBI is genuinely debated and pressure-dependent, and military post-concussion trials at higher pressure are consistently null. The table below synthesizes the strongest study per category with its sample size and effect.
| TBI Type | Evidence Grade | Best Study (N) | Key Finding |
|---|---|---|---|
| Acute severe TBI | Strong | Bennett/Cochrane 2012 (571) | Mortality reduced 31%, NNT=7 |
| Acute moderate TBI | Moderate | Chaturvedi 2024 RCT (variable) | GCS 14.37 vs 13.40 at discharge (p<0.001) |
| Chronic mild TBI / PCS (1.5 ATA) | Moderate / Debated | Weaver 2025 RCT (47) | NSI 10.6 vs 3.6 for sham (p=0.01) |
| Military PCS (2.0-2.4 ATA) | Limited / Null | Cifu 2014 / Miller 2015 (60-71) | No significant benefit over sham |
| Pediatric persistent PCS | Emerging | Hadanny 2022 RCT (25) | Cognitive and executive gains, MRI-confirmed |
This split is the single most important thing to understand about HBOT for TBI. A blanket claim that it does or does not work is wrong in both directions. See how the two dominant dosing schools differ in the Efrati versus Harch protocol comparison, and how acute and chronic strategies diverge in the guide to mild versus severe TBI.
Does HBOT work for chronic concussion?
The chronic mild TBI evidence is real but contested, and pressure appears to matter more than oxygen dose. Multiple civilian trials at 1.5 ATA report significant symptom and cognitive gains, while trials at 2.0 to 2.4 ATA more often fail to separate from sham. Dose, not just presence of oxygen, drives the disagreement in the literature.
Weaver and colleagues (2025, Scientific Reports) ran the largest double-blind trial in this space, randomizing 47 participants with persistent symptoms to 40 sessions of HBOT at 1.5 ATA or sham.1 The HBOT group improved on the Neurobehavioral Symptom Inventory by 10.6 points versus 3.6 for sham (mean difference 7.0, 95% CI 1.7 to 12.3, p=0.01), with additional gains in olfaction, anxiety, sleep, and vestibular symptoms. The authors suggested 80 sessions may outperform 40 for durable benefit.
“In the largest double-blind trial to date, HBOT patients improved their neurobehavioral symptom scores nearly three times more than those receiving sham treatment (10.6 vs 3.6 points, p=0.01), with additional improvements in olfaction, anxiety, sleep, and vestibular complaints.”
Weaver et al., 2025, Scientific Reports
Harch and colleagues (2020, Medical Gas Research) reported a crossover randomized trial of 63 civilian and military patients treated with 40 sessions at 1.5 ATA. HBOT subjects improved significantly on the Neurobehavioral Symptom Inventory, a memory index, depression and anxiety scales, PTSD checklist, sleep quality, and quality of life, with gains persisting at least two months.6 Boussi-Gross and colleagues (2013, PLoS ONE) found that HBOT improved cognitive function and quality of life in patients whose mild TBI symptoms had persisted for years, evidence that a chronic, apparently stable deficit can still respond.13
Harch’s 2022 dosage analysis in Frontiers in Neurology tied the pattern together: across 11 analyzed studies, statistically significant improvement occurred at 40 sessions of 1.5 ATA oxygen and, in one study, at 1.3 ATA pressurized air, with pressure within a narrow range appearing more decisive than oxygen concentration.9 A 2016 meta-analysis by Wang and colleagues in Neurological Sciences reached a similarly cautious-but-positive read on overall TBI outcomes.4 For patients researching timelines, the before and after imaging results track how these changes appear on scans.
Why do military HBOT trials show no benefit?
The four Department of Defense-funded trials of HBOT for military post-concussion symptoms found no significant advantage over sham, and the leading explanation is the sham itself. Most used low-pressure pressurized air (1.2 to 1.3 ATA) as a placebo, and that condition may be mildly therapeutic, shrinking the measurable gap between arms rather than proving no effect.
Cifu and colleagues (2014, Journal of Head Trauma Rehabilitation) treated 60 service members at 1.5 and 2.0 ATA equivalents and found no efficacy signal against sham.10 Wolf and colleagues (2012, Journal of Neurotrauma) tested 2.4 ATA in 50 airmen and again found no significant difference from a 1.3 ATA sham.20 The BIMA trial (Miller et al., 2015, JAMA Internal Medicine), the most robust of the group with 71 participants and 12-month follow-up, saw a directional benefit for HBOT on several measures but most differences did not reach significance; the trial was designed to identify outcomes for future efficacy studies, not to prove efficacy.14 Meehan and colleagues (2019, Journal of Vestibular Research) followed 71 of these participants on balance and mood and found the picture confounded by co-occurring PTSD and depression.19
Biggs and colleagues (2021, Journal of Applied Physiology) recomputed effect sizes across these trials and found meaningful symptomatic and cognitive improvements within both the HBOT and sham groups, which is exactly what you would expect if low-pressure air carries a genuine physiological effect.8 The practical takeaway: a null result against a possibly active placebo is weaker evidence of no benefit than it looks, and it does not transfer cleanly to civilian 1.5 ATA protocols. This distinction matters most for veterans weighing HBOT outside a trial.
Does HBOT help children with post-concussion syndrome?
Pediatric evidence is emerging and limited to one small controlled trial, so it should be read as a promising signal rather than an established treatment. Hadanny and colleagues (2022, Scientific Reports) randomized 25 children aged 8 to 15 with persistent post-concussion symptoms from prior mild-to-moderate TBI to 60 HBOT sessions or sham in a double-blind design.7
The HBOT group showed significant gains in general cognitive score (Cohen’s d=0.598, p=0.01) and executive function (d=0.739, p=0.003), alongside improvement in behavioral measures such as hyperactivity. MRI confirmed microstructural white-matter changes in relevant brain regions, giving the self-report and testing data an objective anchor. With only 25 participants, the result needs replication before it changes practice, but it is consistent with the civilian adult 1.5 to 2.0 ATA findings. Families researching this route should read the dedicated overview of HBOT for concussion before committing to a long course.
Can brain imaging confirm HBOT effects?
Yes, imaging is one of the more persuasive strands of evidence because it does not rely on patient self-report. SPECT and MRI studies repeatedly show increased perfusion and microstructural change in previously injured regions after a course of HBOT, and those changes tend to align with the cognitive domains that improve on testing.
Tal and colleagues (2017, Frontiers in Human Neuroscience) used dynamic susceptibility contrast MRI in 15 patients with prolonged post-concussion syndrome and documented angiogenesis and nerve-fiber regeneration after 60 HBOT sessions.18 The mechanistic rationale is well described: Huang and Obenaus (2011, Medical Gas Research) reviewed how repeated low-pressure HBOT can lower intracranial pressure, reduce secondary injury, and support neurobehavioral recovery.21 Objective imaging is what separates the strongest chronic-TBI studies from open-label anecdote, and it is why the field continues despite the null military trials. The same perfusion changes are visible in the broader work on HBOT for neurological conditions.
What protocol and how many sessions do the trials use?
Effective TBI protocols in the published trials cluster at 1.5 to 2.0 ATA for 40 to 60 sessions of 60 to 90 minutes each, using hard-shell chambers with 100 percent oxygen. Home soft chambers at 1.3 ATA have not been validated for TBI in controlled research. The table below compares the protocols behind the main results.
| Protocol | Pressure | Sessions | Duration | Evidence |
|---|---|---|---|---|
| Harch protocol | 1.5 ATA | 40-80 | 60 min | Multiple RCTs positive for chronic PCS |
| Efrati protocol | 2.0 ATA | 60 | 90 min | RCTs with imaging-confirmed change |
| Chaturvedi 2024 (acute moderate) | 1.4 ATA | 10 | 60 min | RCT, acute adjunct to standard care |
| DoD military trials | 2.0-2.4 ATA | 30-40 | 60-90 min | Null versus low-pressure sham |
Chaturvedi and colleagues (2024, Asian Journal of Neurosurgery) showed the acute-adjunct model works on a short course: 10 daily sessions at 1.4 ATA added to standard care raised discharge GCS to 14.37 versus 13.40 for controls (p<0.001) and improved 3-month functional outcomes.2 Chronic protocols are far longer, which is why cost and access become the deciding factors for most patients.
What does HBOT for TBI cost, and is it covered?
TBI is an off-label indication, so insurance does not cover HBOT for it outside rare VA research programs, and a full course runs $8,000 to $24,000 out of pocket. Effective protocols require a hard chamber at 1.5 to 2.0 ATA, which rules out most home units.
A 40 to 60 session course is the standard chronic-TBI commitment, and at typical clinic rates that lands in the mid five figures. Insurance for HBOT covers 14 UHMS-approved indications, and TBI is not among them, so patients pay directly; the full HBOT cost breakdown shows how session pricing varies by region and chamber type. The HOBIT adaptive Phase II trial (NCT02407028) is testing optimal protocols for severe TBI and could pave the way toward a definitive Phase III study and, eventually, coverage.22 Until then, cost and the strength-of-evidence split above are the two facts that should drive the decision. HBOT is also studied for related recovery goals in athletes recovering from concussion, where the evidence is thinner still.
Is HBOT FDA-approved for traumatic brain injury?
No. The FDA and UHMS recognize 14 approved indications for hyperbaric oxygen, and TBI is not one of them. Its use for brain injury is off-label, meaning a physician may prescribe it but insurers generally will not reimburse it. The strongest supporting data, the 2012 Cochrane mortality finding for severe TBI, still led the reviewers to advise against routine use pending a definitive trial.
How many HBOT sessions does TBI treatment require?
Chronic mild TBI and post-concussion protocols in the published trials use 40 to 60 sessions at 1.5 to 2.0 ATA, and Weaver 2025 suggested 80 sessions may produce more durable benefit than 40. Acute moderate TBI has been treated as a short adjunct: Chaturvedi 2024 used just 10 daily sessions at 1.4 ATA alongside standard care, improving discharge and 3-month outcomes.
Why do some HBOT trials for concussion succeed while others fail?
Pressure and the choice of sham explain most of the disagreement. Civilian trials at 1.5 ATA (Weaver 2025, Harch 2020) show benefit, while military trials at 2.0 to 2.4 ATA (Cifu 2014, Wolf 2012, Miller 2015) do not separate from sham. Because the sham was low-pressure pressurized air that may itself be active, a null result is weaker evidence of no effect than it appears, per Biggs 2021.
Sources
- Weaver LK, Ziemnik R, Deru K, Russo AA. “A double-blind randomized trial of hyperbaric oxygen for persistent symptoms after brain injury.” Scientific Reports. 2025;15:6584. PMID: 40011516. DOI: 10.1038/s41598-025-86631-6
- Chaturvedi J, Mago V, Gupta M, et al. “Hyperbaric Oxygen Therapy (HBOT) in Moderate Traumatic Brain Injury (TBI): A Randomized Controlled Trial.” Asian Journal of Neurosurgery. 2024;20(1):69-74. PMID: 40041595. DOI: 10.1055/s-0044-1791997
- Bennett MH, Trytko BE, Jonker B. “Hyperbaric oxygen therapy for the adjunctive treatment of traumatic brain injury.” Cochrane Database of Systematic Reviews. 2012;12:CD004609. DOI: 10.1002/14651858.CD004609.pub3
- Wang F, Wang Y, Sun T, Yu HL. “Hyperbaric oxygen therapy for the treatment of traumatic brain injury: a meta-analysis.” Neurological Sciences. 2016;37:693-701. DOI: 10.1007/s10072-015-2460-2
- Shahid S, Saeed H, et al. “Hyperbaric oxygen therapy (HBOT) for neurocognitive deficits following traumatic brain injury: a systematic review and meta-analysis.” Annals of Medicine and Surgery. 2025;87(11). DOI: 10.1097/MS9.0000000000003902
- Harch PG, Andrews SR, Rowe CJ, et al. “Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion syndrome: a randomized controlled trial.” Medical Gas Research. 2020;10(1):8-20. DOI: 10.4103/2045-9912.279978
- Hadanny A, Catalogna M, Yaniv S, et al. “Hyperbaric oxygen therapy in children with post-concussion syndrome improves cognitive and behavioral function: a randomized controlled trial.” Scientific Reports. 2022;12:15233. PMID: 36151105. DOI: 10.1038/s41598-022-19395-y
- Biggs AT, Dainer HM, Littlejohn LF. “Effect sizes for symptomatic and cognitive improvements in traumatic brain injury following hyperbaric oxygen therapy.” Journal of Applied Physiology. 2021;130(5):1594-1603. DOI: 10.1152/japplphysiol.01084.2020
- Harch PG. “Systematic Review and Dosage Analysis: Hyperbaric Oxygen Therapy Efficacy in Mild Traumatic Brain Injury Persistent Postconcussion Syndrome.” Frontiers in Neurology. 2022;13:815056. DOI: 10.3389/fneur.2022.815056
- Cifu DX, Hart BB, West SL, Walker W, Carne W. “The effect of hyperbaric oxygen on persistent postconcussion symptoms.” Journal of Head Trauma Rehabilitation. 2014;29(1):11-20. PMID: 24052094. DOI: 10.1097/HTR.0b013e3182a6aaf0
- Centers for Disease Control and Prevention. “Facts About TBI.” National Center for Injury Prevention and Control, 2024 (2021 mortality and 2020 hospitalization data). cdc.gov
- Jusoh AF, et al. “Hyperbaric Oxygen Therapy in Traumatic Brain Injury: A Comprehensive Structure Review.” Undersea and Hyperbaric Medicine. Ahead of print, 2026. uhms.org (article 799, ahead of print)
- Boussi-Gross R, Golan H, Fishlev G, et al. “Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury: randomized prospective trial.” PLoS ONE. 2013;8(11):e79995. PMID: 24260334. DOI: 10.1371/journal.pone.0079995
- Miller RS, Weaver LK, Bahraini N, et al. “Effects of hyperbaric oxygen on symptoms and quality of life among service members with persistent postconcussion symptoms: a randomized clinical trial.” JAMA Internal Medicine. 2015;175(1):43-52. PMID: 25401463. DOI: 10.1001/jamainternmed.2014.5479
- Rockswold SB, Rockswold GL, Zaun DA, Liu J. “A prospective, randomized Phase II clinical trial to evaluate the effect of combined hyperbaric and normobaric hyperoxia on cerebral metabolism, intracranial pressure, oxygen toxicity, and clinical outcome in severe traumatic brain injury.” Journal of Neurosurgery. 2013;118(6):1317-1328. DOI: 10.3171/2013.2.JNS121468
- Rockswold GL, Ford SE, Anderson DC, Bergman TA, Sherman RE. “Results of a prospective randomized trial for treatment of severely brain-injured patients with hyperbaric oxygen.” Journal of Neurosurgery. 1992;76(6):929-934. PMID: 1588426. DOI: 10.3171/jns.1992.76.6.0929
- Daly S, Thorpe M, Rockswold S, et al. “Hyperbaric Oxygen Therapy in the Treatment of Acute Severe Traumatic Brain Injury: A Systematic Review.” Journal of Neurotrauma. 2018;35(4):623-629. DOI: 10.1089/neu.2017.5225
- Tal S, Hadanny A, Sasson E, Suzin G, Efrati S. “Hyperbaric Oxygen Therapy Can Induce Angiogenesis and Regeneration of Nerve Fibers in Traumatic Brain Injury Patients.” Frontiers in Human Neuroscience. 2017;11:508. PMID: 29097988. DOI: 10.3389/fnhum.2017.00508
- Meehan A, Hebert D, Deru K, Weaver LK. “Longitudinal study of hyperbaric oxygen intervention on balance and affective symptoms in military service members with persistent post-concussive symptoms.” Journal of Vestibular Research. 2019;29(4):205-219. DOI: 10.3233/VES-180671
- Wolf G, Cifu D, Baugh L, Carne W, Profenna L. “The effect of hyperbaric oxygen on symptoms after mild traumatic brain injury.” Journal of Neurotrauma. 2012;29(17):2606-2612. PMID: 23031217. DOI: 10.1089/neu.2012.2549
- Huang L, Obenaus A. “Hyperbaric oxygen therapy for traumatic brain injury.” Medical Gas Research. 2011;1:21. DOI: 10.1186/2045-9912-1-21
- Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial. ClinicalTrials.gov identifier NCT02407028. clinicaltrials.gov/study/NCT02407028
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
